Cargando…
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
Tyrosine kinase inhibitors (TKIs) that primarily target angiogenesis are approved to treat several cancers in the metastatic setting; however, resistance is common. Sequential treatment or ‘switching’ from one TKI to another following failure can be effective, but predicting which drugs will have cr...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675057/ https://www.ncbi.nlm.nih.gov/pubmed/31369645 http://dx.doi.org/10.1371/journal.pone.0220101 |